Literature DB >> 33121225

A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia

Wanlu Ma1, Jiawei Zhao2, Lu Zhang3.   

Abstract

Entities:  

Keywords:  Waldenstrom macroglobulinemia; Rituximab-induced thrombocytopenia; Ixazomib

Mesh：

Substances：

Year:  2020        PMID： 33121225      PMCID： PMC7927456          DOI： 10.4274/tjh.galenos.2020.2020.0521

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN： 1300-7777            Impact factor:   1.831


× No keyword cloud information.
  7 in total

Review 1.  Updates in prognostication and treatment of Waldenström's macroglobulinemia.

Authors:  Pooja Advani; Aneel Paulus; Sikander Ailawadhi
Journal:  Hematol Oncol Stem Cell Ther       Date:  2019-05-28

2.  Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series.

Authors:  David H Vesole; Joshua Richter; Noa Biran; Laura McBride; Palka Anand; Mei Huang; Anita-Zahlten Kumeli; Zandra Klippel; Karim Iskander; David S Siegel
Journal:  Leuk Lymphoma       Date:  2017-06-05

3.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

4.  Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.

Authors:  Jorge J Castillo; Kirsten Meid; Joshua N Gustine; Toni Dubeau; Patricia Severns; Zachary R Hunter; Guang Yang; Lian Xu; Steven P Treon
Journal:  Clin Cancer Res       Date:  2018-04-16       Impact factor: 12.531

5.  Rituximab-induced thrombocytopenia: a cohort study.

Authors:  Thijs J Giezen; Aukje K Mantel-Teeuwisse; Maarten J ten Berg; Sabine M J M Straus; Hubert G M Leufkens; Wouter W van Solinge; Toine C G Egberts
Journal:  Eur J Haematol       Date:  2012-07-05       Impact factor: 2.997

Review 6.  Waldenström's macroglobulinemia.

Authors:  Meletios A Dimopoulos; Athanasios Anagnostopoulos
Journal:  Best Pract Res Clin Haematol       Date:  2005       Impact factor: 3.020

7.  Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).

Authors:  Morie A Gertz; Montserrat Rue; Emily Blood; Lynne S Kaminer; David H Vesole; Philip R Greipp
Journal:  Leuk Lymphoma       Date:  2004-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.